Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03397862 · ClinicalTrials.gov registry record · Phase 1

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

A Phase 1 study, sponsored by Corium.

Completed
Registry status
Phase 1
Development phase
256
Enrollment target

NCT03397862: Completed Phase 1 study, sponsored by Corium.

NCT03397862 is a Phase 1 study that has completed, run by Corium. The registered enrollment target is 256 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (327% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03397862, a Phase 1 study, has completed, sponsored by Corium.

COMPLETED
Registry status
Phase 1
Development phase
256 participants
Enrollment target

Study Summary

A study to assess the skin irritation and sensitization potential of Corplex™ Donepezil Transdermal Delivery System (TDS)

Primary Outcome

Mean Cumulative skin irritation score is determined by averaging the combined Dermal Response score (8-point categorical scale using numeric values) and the Other Effects score (6-point categorical scale using alphabet letters equivalent to numeric values) during the induction phase of the study.

Interventions

  • DRUG Donepezil TDS
  • DRUG Vehicle TDS

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2017-11-14
Est. Completion 2018-04-02
Phase Phase 1
Corium

8 total trials

What the finished NCT03397862 record still lists

NCT03397862 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (327% higher).

The record links to 0 conditions, and to 2 interventions - of which Donepezil TDS is the first listed.

NCT03397862 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03397862 about?

NCT03397862 is a clinical study titled "A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System". A study to assess the skin irritation and sensitization potential of Corplex™ Donepezil Transdermal Delivery System (TDS)

What is the current status of trial NCT03397862?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 256 participants. The study started on 2017-11-14. Estimated completion is 2018-04-02.

What interventions are being tested in trial NCT03397862?

The interventions under investigation include: Donepezil TDS (DRUG), Vehicle TDS (DRUG).

Who is sponsoring clinical trial NCT03397862?

This trial is sponsored by Corium, which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03397862's enrollment target sits among peer trials

256 168th of 2000 higher than 1,833 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02464696 · 256 participants · NA

    Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

  • NCT03793062 · 256 participants

    Genetic and Epigenetic Basis of Chronic Wounds

  • NCT04322318 · 256 participants · Phase 2

    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • NCT04468360 · 256 participants · Phase 2

    Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03397862, the US trial registry maintained by the National Library of Medicine. NCT03397862 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.